The University of Chicago Header Logo

Connection

Ayman Al-Hendy to Uterine Neoplasms

Back to Details
This is a "connection" page, showing publications Ayman Al-Hendy has written about Uterine Neoplasms.
Ayman Al-Hendy
Connection Strength
41.865
Uterine Neoplasms
  1. A plain language summary describing changes in pain associated with uterine fibroids among women receiving relugolix combination therapy. Pain Manag. 2024 Sep; 14(9):469-476.
    View in: PubMed
    Score: 0.715
  2. Unraveling the Role of Bromodomain and Extra-Terminal Proteins in Human Uterine Leiomyosarcoma. Cells. 2024 Aug 28; 13(17).
    View in: PubMed
    Score: 0.707
  3. Uterine fibroids: current research on novel drug targets and innovative therapeutic strategies. Expert Opin Ther Targets. 2024 Aug; 28(8):669-687.
    View in: PubMed
    Score: 0.705
  4. Changes in symptom burden and quality of life among women with uterine fibroids receiving relugolix combination therapy: a plain language summary. J Comp Eff Res. 2024 08; 13(8):e230194.
    View in: PubMed
    Score: 0.699
  5. Comprehensive Review of Uterine Leiomyosarcoma: Pathogenesis, Diagnosis, Prognosis, and Targeted Therapy. Cells. 2024 Jun 26; 13(13).
    View in: PubMed
    Score: 0.699
  6. Altered extracellular matrix-related pathways accelerate the transition from normal to prefibroid myometrium in Black women. Am J Obstet Gynecol. 2024 Sep; 231(3):324.e1-324.e12.
    View in: PubMed
    Score: 0.695
  7. Quality of life improvements in women with uterine fibroids treated with relugolix combination therapy during the LIBERTY long-term extension study: A descriptive subgroup analysis in women with anemia at baseline. Int J Gynaecol Obstet. 2024 May; 165(2):431-441.
    View in: PubMed
    Score: 0.688
  8. Empowering Strategies for Lifestyle Interventions, Diet Modifications, and Environmental Practices for Uterine Fibroid Prevention; Unveiling the LIFE UP Awareness. Nutrients. 2024 Mar 12; 16(6).
    View in: PubMed
    Score: 0.685
  9. Survivin-Sodium Iodide Symporter Reporter as a Non-Invasive Diagnostic Marker to Differentiate Uterine Leiomyosarcoma from Leiomyoma. Cells. 2023 12 13; 12(24).
    View in: PubMed
    Score: 0.673
  10. Evidence-Based Approach for Secondary Prevention of Uterine Fibroids (The ESCAPE Approach). Int J Mol Sci. 2023 Nov 04; 24(21).
    View in: PubMed
    Score: 0.668
  11. Current and Emerging Treatment Options for Uterine Fibroids. Drugs. 2023 Dec; 83(18):1649-1675.
    View in: PubMed
    Score: 0.668
  12. The combination of natural compounds Crila and epigallocatechin gallate showed enhanced antiproliferative effects on human uterine fibroid cells compared with single treatments. F S Sci. 2023 11; 4(4):341-349.
    View in: PubMed
    Score: 0.662
  13. LIBERTY randomized withdrawal study: relugolix combination therapy for heavy menstrual bleeding associated with uterine fibroids. Am J Obstet Gynecol. 2023 12; 229(6):662.e1-662.e25.
    View in: PubMed
    Score: 0.660
  14. GnRH agonists and antagonists in therapy of symptomatic uterine fibroids - current roles and future perspectives. Expert Opin Pharmacother. 2023 Sep-Dec; 24(16):1799-1809.
    View in: PubMed
    Score: 0.659
  15. Uterine Fibroids: A Podcast on Patient and Physician Perspectives on Medical Management and a New Medical Therapy (Relugolix Combination Therapy). Adv Ther. 2023 10; 40(10):4127-4133.
    View in: PubMed
    Score: 0.658
  16. A plain language summary of the long-term relugolix combination therapy study for uterine fibroids. J Comp Eff Res. 2023 08; 12(8):e230069.
    View in: PubMed
    Score: 0.655
  17. Epigenetic Modulation of Inflammatory Pathways in Myometrial Stem Cells and Risk of Uterine Fibroids. Int J Mol Sci. 2023 Jul 19; 24(14).
    View in: PubMed
    Score: 0.655
  18. Efficacy and safety of vilaprisan in women with uterine fibroids: data from the ASTEROID 3 randomized controlled trial. F S Sci. 2023 Nov; 4(4):317-326.
    View in: PubMed
    Score: 0.653
  19. A plain language summary of the safety of relugolix combination therapy and improvement in symptoms in women with uterine fibroids from the LIBERTY 1 and LIBERTY 2 studies. Pain Manag. 2023 Apr; 13(4):205-211.
    View in: PubMed
    Score: 0.647
  20. EZH2 activates Wnt/ß-catenin signaling in human uterine fibroids, which is inhibited by the natural compound methyl jasmonate. F S Sci. 2023 08; 4(3):239-256.
    View in: PubMed
    Score: 0.646
  21. The Functional Role and Regulatory Mechanism of FTO m6A RNA Demethylase in Human Uterine Leiomyosarcoma. Int J Mol Sci. 2023 Apr 27; 24(9).
    View in: PubMed
    Score: 0.644
  22. Progesterone Signaling and Uterine Fibroid Pathogenesis; Molecular Mechanisms and Potential Therapeutics. Cells. 2023 04 09; 12(8).
    View in: PubMed
    Score: 0.642
  23. Update on the Role and Regulatory Mechanism of Extracellular Matrix in the Pathogenesis of Uterine Fibroids. Int J Mol Sci. 2023 Mar 17; 24(6).
    View in: PubMed
    Score: 0.639
  24. Quality of life with relugolix combination therapy for uterine fibroids: LIBERTY randomized trials. Am J Obstet Gynecol. 2023 03; 228(3):320.e1-320.e11.
    View in: PubMed
    Score: 0.624
  25. Long-term Relugolix Combination Therapy for Symptomatic Uterine Leiomyomas. Obstet Gynecol. 2022 12 01; 140(6):920-930.
    View in: PubMed
    Score: 0.623
  26. Comprehensive Review of Uterine Fibroids: Developmental Origin, Pathogenesis, and Treatment. Endocr Rev. 2022 07 13; 43(4):678-719.
    View in: PubMed
    Score: 0.610
  27. The Functional Role and Regulatory Mechanism of Bromodomain-Containing Protein 9 in Human Uterine Leiomyosarcoma. Cells. 2022 07 10; 11(14).
    View in: PubMed
    Score: 0.610
  28. Relugolix Combination Therapy for Uterine Leiomyoma-Associated Pain in the LIBERTY Randomized Trials. Obstet Gynecol. 2022 06 01; 139(6):1070-1081.
    View in: PubMed
    Score: 0.602
  29. An evaluation of relugolix/estradiol/norethindrone acetate for the treatment of heavy menstrual bleeding associated with uterine fibroids in premenopausal women. Expert Opin Pharmacother. 2022 Mar; 23(4):421-429.
    View in: PubMed
    Score: 0.591
  30. Current approaches to overcome the side effects of GnRH analogs in the treatment of patients with uterine fibroids. Expert Opin Drug Saf. 2022 Apr; 21(4):477-486.
    View in: PubMed
    Score: 0.580
  31. Reduction of Heavy Menstrual Bleeding in Women Not Designated as Responders to Elagolix Plus Add Back Therapy for Uterine Fibroids. J Womens Health (Larchmt). 2022 05; 31(5):698-705.
    View in: PubMed
    Score: 0.578
  32. Treatment of Uterine Fibroid Symptoms with Relugolix Combination Therapy. N Engl J Med. 2021 02 18; 384(7):630-642.
    View in: PubMed
    Score: 0.554
  33. The Significance of Measuring Vitamin D Serum Levels in Women with Uterine Fibroids. Reprod Sci. 2021 08; 28(8):2098-2109.
    View in: PubMed
    Score: 0.542
  34. Vitamins and Uterine Fibroids: Current Data on Pathophysiology and Possible Clinical Relevance. Int J Mol Sci. 2020 Aug 01; 21(15).
    View in: PubMed
    Score: 0.533
  35. Molecular Bio-Imaging Probe for Non-Invasive Differentiation Between Human Leiomyoma Versus Leiomyosarcoma. Reprod Sci. 2020 02; 27(2):644-654.
    View in: PubMed
    Score: 0.513
  36. Vitamin D and uterine fibroids: preclinical evidence is in; time for an overdue clinical study! Fertil Steril. 2020 01; 113(1):89-90.
    View in: PubMed
    Score: 0.512
  37. Simvastatin and uterine fibroids: opportunity for a novel therapeutic option. Fertil Steril. 2018 12; 110(7):1272-1273.
    View in: PubMed
    Score: 0.475
  38. Endocrine disruptor exposure during development increases incidence of uterine fibroids by altering DNA repair in myometrial stem cells. Biol Reprod. 2018 10 01; 99(4):735-748.
    View in: PubMed
    Score: 0.469
  39. Uterine fibroid therapy: the pharmacokinetic considerations. Expert Opin Drug Metab Toxicol. 2018 Sep; 14(9):887-889.
    View in: PubMed
    Score: 0.464
  40. Expanding upon the Human Myometrial Stem Cell Hypothesis and the Role of Race, Hormones, Age, and Parity in a Profibroid Environment. Am J Pathol. 2018 10; 188(10):2293-2306.
    View in: PubMed
    Score: 0.464
  41. Ulipristal Acetate for Treatment of Symptomatic Uterine Leiomyomas: A Randomized Controlled Trial. Obstet Gynecol. 2018 03; 131(3):431-439.
    View in: PubMed
    Score: 0.451
  42. Successes and failures of uterine leiomyoma drug discovery. Expert Opin Drug Discov. 2018 02; 13(2):169-177.
    View in: PubMed
    Score: 0.445
  43. Uterine Leiomyoma: New Perspectives on an Old Disease. Semin Reprod Med. 2017 11; 35(6):471-472.
    View in: PubMed
    Score: 0.441
  44. Uterine Fibroids: Burden and Unmet Medical Need. Semin Reprod Med. 2017 11; 35(6):473-480.
    View in: PubMed
    Score: 0.441
  45. Origin of Uterine Fibroids: Conversion of Myometrial Stem Cells to Tumor-Initiating Cells. Semin Reprod Med. 2017 11; 35(6):481-486.
    View in: PubMed
    Score: 0.441
  46. Silencing Med12 Gene Reduces Proliferation of Human Leiomyoma Cells Mediated via Wnt/ß-Catenin Signaling Pathway. Endocrinology. 2017 03 01; 158(3):592-603.
    View in: PubMed
    Score: 0.421
  47. Estrogen Receptors and Signaling in Fibroids: Role in Pathobiology and Therapeutic Implications. Reprod Sci. 2017 09; 24(9):1235-1244.
    View in: PubMed
    Score: 0.413
  48. Identification of Polycomb Group Protein EZH2-Mediated DNA Mismatch Repair Gene MSH2 in Human Uterine Fibroids. Reprod Sci. 2016 10; 23(10):1314-25.
    View in: PubMed
    Score: 0.395
  49. Magnetic nanoparticles as a new approach to improve the efficacy of gene therapy against differentiated human uterine fibroid cells and tumor-initiating stem cells. Fertil Steril. 2016 06; 105(6):1638-1648.e8.
    View in: PubMed
    Score: 0.394
  50. Targeted Adenoviral Vector Demonstrates Enhanced Efficacy for In Vivo Gene Therapy of Uterine Leiomyoma. Reprod Sci. 2016 Apr; 23(4):464-74.
    View in: PubMed
    Score: 0.391
  51. Vitamin D3 Inhibits Wnt/ß-Catenin and mTOR Signaling Pathways in Human Uterine Fibroid Cells. J Clin Endocrinol Metab. 2016 04; 101(4):1542-51.
    View in: PubMed
    Score: 0.390
  52. The Mechanism and Function of Epigenetics in Uterine Leiomyoma Development. Reprod Sci. 2016 Feb; 23(2):163-75.
    View in: PubMed
    Score: 0.370
  53. 1,25-dihydroxyvitamin D3 regulates expression of sex steroid receptors in human uterine fibroid cells. J Clin Endocrinol Metab. 2015 Apr; 100(4):E572-82.
    View in: PubMed
    Score: 0.364
  54. Novel MED12 gene somatic mutations in women from the Southern United States with symptomatic uterine fibroids. Mol Genet Genomics. 2015 Apr; 290(2):505-11.
    View in: PubMed
    Score: 0.357
  55. Green tea extract inhibition of human leiomyoma cell proliferation is mediated via catechol-O-methyltransferase. Gynecol Obstet Invest. 2014; 78(2):109-18.
    View in: PubMed
    Score: 0.349
  56. Paricalcitol, a vitamin d receptor activator, inhibits tumor formation in a murine model of uterine fibroids. Reprod Sci. 2014 Sep; 21(9):1108-19.
    View in: PubMed
    Score: 0.348
  57. 1,25-dihydroxyvitamin d3 reduces extracellular matrix-associated protein expression in human uterine fibroid cells. Biol Reprod. 2013 Dec; 89(6):150.
    View in: PubMed
    Score: 0.337
  58. Racial and ethnic differences in the pathogenesis and clinical manifestations of uterine leiomyoma. Semin Reprod Med. 2013 Sep; 31(5):370-9.
    View in: PubMed
    Score: 0.329
  59. Targeting adenoviral vectors for enhanced gene therapy of uterine leiomyomas. Hum Reprod. 2013 Sep; 28(9):2398-406.
    View in: PubMed
    Score: 0.326
  60. Vitamin D3 inhibits expression and activities of matrix metalloproteinase-2 and -9 in human uterine fibroid cells. Hum Reprod. 2013 Sep; 28(9):2407-16.
    View in: PubMed
    Score: 0.326
  61. 1,25-dihydroxyvitamin D3 treatment shrinks uterine leiomyoma tumors in the Eker rat model. Biol Reprod. 2012 Apr; 86(4):116.
    View in: PubMed
    Score: 0.300
  62. Medical treatment of uterine leiomyoma. Reprod Sci. 2012 Apr; 19(4):339-53.
    View in: PubMed
    Score: 0.297
  63. Adipocytes enhance the proliferation of human leiomyoma cells via TNF-a proinflammatory cytokine. Reprod Sci. 2011 Dec; 18(12):1186-92.
    View in: PubMed
    Score: 0.292
  64. Vitamin D inhibits proliferation of human uterine leiomyoma cells via catechol-O-methyltransferase. Fertil Steril. 2011 Jan; 95(1):247-53.
    View in: PubMed
    Score: 0.268
  65. Green tea extract inhibits proliferation of uterine leiomyoma cells in vitro and in nude mice. Am J Obstet Gynecol. 2010 Mar; 202(3):289.e1-9.
    View in: PubMed
    Score: 0.257
  66. Antiproliferative and proapoptotic effects of epigallocatechin gallate on human leiomyoma cells. Fertil Steril. 2010 Oct; 94(5):1887-93.
    View in: PubMed
    Score: 0.252
  67. Towards fibroid gene therapy: adenovirus-mediated delivery of herpes simplex virus 1 thymidine kinase gene/ganciclovir shrinks uterine leiomyoma in the Eker rat model. Gynecol Obstet Invest. 2009; 68(1):19-32.
    View in: PubMed
    Score: 0.243
  68. Gene therapy targeting leiomyoma: adenovirus-mediated delivery of dominant-negative estrogen receptor gene shrinks uterine tumors in Eker rat model. Fertil Steril. 2010 Jan; 93(1):239-50.
    View in: PubMed
    Score: 0.239
  69. Memy I: a novel murine model for uterine leiomyoma using adenovirus-enhanced human fibroid explants in severe combined immune deficiency mice. Am J Obstet Gynecol. 2008 Aug; 199(2):156.e1-8.
    View in: PubMed
    Score: 0.228
  70. Molecular genetics and racial disparities of uterine leiomyomas. Best Pract Res Clin Obstet Gynaecol. 2008 Aug; 22(4):589-601.
    View in: PubMed
    Score: 0.226
  71. Adenovirus-mediated delivery of a dominant-negative estrogen receptor gene in uterine leiomyoma cells abrogates estrogen- and progesterone-regulated gene expression. J Clin Endocrinol Metab. 2007 Oct; 92(10):3949-57.
    View in: PubMed
    Score: 0.216
  72. Estrogen metabolite 2-methoxyestradiol induces apoptosis and inhibits cell proliferation and collagen production in rat and human leiomyoma cells: a potential medicinal treatment for uterine fibroids. J Soc Gynecol Investig. 2006 Dec; 13(8):542-50.
    View in: PubMed
    Score: 0.206
  73. Gene therapy of uterine leiomyoma: adenovirus-mediated herpes simplex virus thymidine kinase/ganciclovir treatment inhibits growth of human and rat leiomyoma cells in vitro and in a nude mouse model. Gynecol Obstet Invest. 2007; 63(2):61-70.
    View in: PubMed
    Score: 0.203
  74. Ethnic distribution of estrogen receptor-alpha polymorphism is associated with a higher prevalence of uterine leiomyomas in black Americans. Fertil Steril. 2006 Sep; 86(3):686-93.
    View in: PubMed
    Score: 0.202
  75. Hormonal regulation of catechol-O-methyl transferase activity in women with uterine leiomyomas. Fertil Steril. 2006 Jul; 86(1):259-62.
    View in: PubMed
    Score: 0.199
  76. Gene therapy and uterine leiomyoma: a review. Hum Reprod Update. 2006 Jul-Aug; 12(4):385-400.
    View in: PubMed
    Score: 0.198
  77. Catechol-O-methyltransferase polymorphism is associated with increased uterine leiomyoma risk in different ethnic groups. J Soc Gynecol Investig. 2006 Feb; 13(2):136-44.
    View in: PubMed
    Score: 0.195
  78. Gene therapy of uterine leiomyomas: adenovirus-mediated expression of dominant negative estrogen receptor inhibits tumor growth in nude mice. Am J Obstet Gynecol. 2004 Nov; 191(5):1621-31.
    View in: PubMed
    Score: 0.179
  79. Surgical myomectomy followed by oral Myfembree vs standard of care (SOUL trial): Study protocol for a randomized control trial. PLoS One. 2024; 19(7):e0306053.
    View in: PubMed
    Score: 0.175
  80. Multiomic analysis of uterine leiomyomas in self-described Black and White women: molecular insights into health disparities. Am J Obstet Gynecol. 2024 Sep; 231(3):321.e1-321.e11.
    View in: PubMed
    Score: 0.173
  81. Management of Uterine Fibroids and Sarcomas: The Palermo Position Paper. Gynecol Obstet Invest. 2024; 89(2):73-86.
    View in: PubMed
    Score: 0.171
  82. Relugolix combination therapy in Black/African American women with symptomatic uterine fibroids: LIBERTY Long-Term Extension study. Am J Obstet Gynecol. 2024 02; 230(2):237.e1-237.e11.
    View in: PubMed
    Score: 0.166
  83. Targeting Class I Histone Deacetylases in Human Uterine Leiomyosarcoma. Cells. 2022 Nov 27; 11(23).
    View in: PubMed
    Score: 0.157
  84. Linzagolix with and without hormonal add-back therapy for the treatment of symptomatic uterine fibroids: two randomised, placebo-controlled, phase 3 trials. Lancet. 2022 09 17; 400(10356):896-907.
    View in: PubMed
    Score: 0.154
  85. Human Myometrial and Uterine Fibroid Stem Cell-Derived Organoids for Intervening the Pathophysiology of Uterine Fibroid. Reprod Sci. 2022 09; 29(9):2607-2619.
    View in: PubMed
    Score: 0.151
  86. Adverse childhood experiences and health-related quality of life among women undergoing hysterectomy for uterine leiomyoma. Am J Obstet Gynecol. 2022 08; 227(2):351-353.e5.
    View in: PubMed
    Score: 0.150
  87. A Call-to-Action for Clinicians to Implement Evidence-Based Best Practices When Caring for Women with Uterine Fibroids. Reprod Sci. 2022 04; 29(4):1188-1196.
    View in: PubMed
    Score: 0.148
  88. Simvastatin inhibits stem cell proliferation in human leiomyoma via TGF-ß3 and Wnt/ß-Catenin pathways. J Cell Mol Med. 2022 03; 26(5):1684-1698.
    View in: PubMed
    Score: 0.148
  89. Evaluation of Hedgehog Pathway Inhibitors as a Therapeutic Option for Uterine Leiomyosarcoma Using the Xenograft Model. Reprod Sci. 2022 03; 29(3):781-790.
    View in: PubMed
    Score: 0.145
  90. Simvastatin modulates estrogen signaling in uterine leiomyoma via regulating receptor palmitoylation, trafficking and degradation. Pharmacol Res. 2021 10; 172:105856.
    View in: PubMed
    Score: 0.144
  91. Proteogenomic landscape of uterine leiomyomas from hereditary leiomyomatosis and renal cell cancer patients. Sci Rep. 2021 04 30; 11(1):9371.
    View in: PubMed
    Score: 0.140
  92. Targeting Hedgehog Pathway and DNA Methyltransferases in Uterine Leiomyosarcoma Cells. Cells. 2020 12 31; 10(1).
    View in: PubMed
    Score: 0.137
  93. The role of endocrine-disrupting chemicals in uterine fibroid pathogenesis. Curr Opin Endocrinol Diabetes Obes. 2020 12; 27(6):380-387.
    View in: PubMed
    Score: 0.136
  94. Summary of the Proceedings of the Basic Science of Uterine Fibroids Meeting: New Developments February 28, 2020. F S Sci. 2021 02; 2(1):88-100.
    View in: PubMed
    Score: 0.136
  95. Non-hormonal mediators of uterine fibroid growth. Curr Opin Obstet Gynecol. 2020 10; 32(5):361-370.
    View in: PubMed
    Score: 0.135
  96. Elagolix Treatment for Up to 12 Months in Women With Heavy Menstrual Bleeding and Uterine Leiomyomas. Obstet Gynecol. 2020 06; 135(6):1313-1326.
    View in: PubMed
    Score: 0.132
  97. The Selective Progesterone Receptor Modulator Ulipristal Acetate Inhibits the Activity of the Glucocorticoid Receptor. J Clin Endocrinol Metab. 2020 03 01; 105(3).
    View in: PubMed
    Score: 0.129
  98. Uterine fibroids in menopause and perimenopause. Menopause. 2020 02; 27(2):238-242.
    View in: PubMed
    Score: 0.129
  99. H19 lncRNA identified as a master regulator of genes that drive uterine leiomyomas. Oncogene. 2019 07; 38(27):5356-5366.
    View in: PubMed
    Score: 0.122
  100. 1,25 Dihydroxyvitamin D3 Enhances the Antifibroid Effects of Ulipristal Acetate in Human Uterine Fibroids. Reprod Sci. 2019 06; 26(6):812-828.
    View in: PubMed
    Score: 0.119
  101. Mediator Kinase Disruption in MED12-Mutant Uterine Fibroids From Hispanic Women of South Texas. J Clin Endocrinol Metab. 2018 11 01; 103(11):4283-4292.
    View in: PubMed
    Score: 0.118
  102. Elagolix Alone or With Add-Back Therapy in Women With Heavy Menstrual Bleeding and Uterine Leiomyomas: A Randomized Controlled Trial. Obstet Gynecol. 2018 11; 132(5):1252-1264.
    View in: PubMed
    Score: 0.118
  103. Burden, Prevalence, and Treatment of Uterine Fibroids: A Survey of U.S. Women. J Womens Health (Larchmt). 2018 11; 27(11):1359-1367.
    View in: PubMed
    Score: 0.117
  104. A Preliminary Study: Human Fibroid Stro-1+/CD44+ Stem Cells Isolated From Uterine Fibroids Demonstrate Decreased DNA Repair and Genomic Integrity Compared to Adjacent Myometrial Stro-1+/CD44+ Cells. Reprod Sci. 2019 05; 26(5):619-638.
    View in: PubMed
    Score: 0.115
  105. Non-coding RNAs: an important regulatory mechanism in pathogenesis of uterine fibroids. Fertil Steril. 2018 05; 109(5):802-803.
    View in: PubMed
    Score: 0.114
  106. Uterine Fibroids: Bridging Genomic Defects and Chronic Inflammation. Semin Reprod Med. 2017 11; 35(6):494-498.
    View in: PubMed
    Score: 0.110
  107. Oxidative stress: a key regulator of leiomyoma cell survival. Fertil Steril. 2017 06; 107(6):1387-1394.e1.
    View in: PubMed
    Score: 0.106
  108. Developmental Exposure to Endocrine Disruptors Expands Murine Myometrial Stem Cell Compartment as a Prerequisite to Leiomyoma Tumorigenesis. Stem Cells. 2017 03; 35(3):666-678.
    View in: PubMed
    Score: 0.103
  109. Berberine Inhibits Uterine Leiomyoma Cell Proliferation via Downregulation of Cyclooxygenase 2 and Pituitary Tumor-Transforming Gene 1. Reprod Sci. 2017 07; 24(7):1005-1013.
    View in: PubMed
    Score: 0.103
  110. Hypovitaminosis D and high serum transforming growth factor beta-3: important biomarkers for uterine fibroids risk. Fertil Steril. 2016 12; 106(7):1648-1649.
    View in: PubMed
    Score: 0.103
  111. Endocrine-disrupting chemicals and uterine fibroids. Fertil Steril. 2016 09 15; 106(4):967-77.
    View in: PubMed
    Score: 0.101
  112. Role of vitamin D in uterine fibroid biology. Fertil Steril. 2015 Sep; 104(3):698-706.
    View in: PubMed
    Score: 0.093
  113. Stro-1/CD44 as putative human myometrial and fibroid stem cell markers. Fertil Steril. 2015 Jul; 104(1):225-34.e3.
    View in: PubMed
    Score: 0.093
  114. Novel effects of simvastatin on uterine fibroid tumors: in vitro and patient-derived xenograft mouse model study. Am J Obstet Gynecol. 2015 Aug; 213(2):196.e1-8.
    View in: PubMed
    Score: 0.092
  115. Berberine inhibits the proliferation of human uterine leiomyoma cells. Fertil Steril. 2015 Apr; 103(4):1098-106.
    View in: PubMed
    Score: 0.091
  116. Nicotinamide adenine dinucleotide phosphate oxidase is differentially regulated in normal myometrium versus leiomyoma. Reprod Sci. 2014 Sep; 21(9):1145-52.
    View in: PubMed
    Score: 0.085
  117. Uterine fibroids are characterized by an impaired antioxidant cellular system: potential role of hypoxia in the pathophysiology of uterine fibroids. J Assist Reprod Genet. 2013 Jul; 30(7):969-74.
    View in: PubMed
    Score: 0.082
  118. Towards non-surgical therapy for uterine fibroids: catechol-O-methyl transferase inhibitor shrinks uterine fibroid lesions in the Eker rat model. Hum Reprod. 2011 Nov; 26(11):3008-18.
    View in: PubMed
    Score: 0.072
  119. 1,25-Dihydroxyvitamin D3 reduces TGF-beta3-induced fibrosis-related gene expression in human uterine leiomyoma cells. J Clin Endocrinol Metab. 2011 Apr; 96(4):E754-62.
    View in: PubMed
    Score: 0.069
  120. Regulatory roles of NAMPT and NAD+ metabolism in uterine leiomyoma progression: Implications for ECM accumulation, stemness, and microenvironment. Redox Biol. 2024 Dec; 78:103411.
    View in: PubMed
    Score: 0.045
  121. Potential nonhormonal therapeutics for medical treatment of leiomyomas. Semin Reprod Med. 2004 May; 22(2):121-30.
    View in: PubMed
    Score: 0.043
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.